Age and rate of cognitive decline in Alzheimer disease: implications for clinical trials.
about
Clinical and Demographic Factors Associated with the Cognitive and Emotional Efficacy of Regular Musical Activities in Dementia.The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement.Rates of decline in Alzheimer disease decrease with age.Using mice to model Alzheimer's dementia: an overview of the clinical disease and the preclinical behavioral changes in 10 mouse modelsEvaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer's disease: analysis of effects of baseline features on treatment response.Cognitive decline in patients with Alzheimer's disease and its related factors in a memory clinic setting, Shanghai, China.Patients with moderate Alzheimer's disease engage in verbal reminiscence with the support of a computer-aided program: a pilot study.NeuroTransDB: highly curated and structured transcriptomic metadata for neurodegenerative diseases.Advances in designs for Alzheimer's disease clinical trials.Effect of study partner on the conduct of Alzheimer disease clinical trialsTechnology-Aided Programs to Support Positive Verbal and Physical Engagement in Persons with Moderate or Severe Alzheimer's DiseaseHigher rates of decline for women and apolipoprotein E epsilon4 carriers.Biomarker-driven therapeutic management of Alzheimer's disease: establishing the foundations.Biochemical and Radiological Markers of Alzheimer's Disease Progression.Characterization of AD-like phenotype in aged APPSwe/PS1dE9 mice.Promoting supported ambulation in persons with advanced Alzheimer's disease: a pilot study.The role of neuroinflammation and amyloid in cognitive impairment in an APP/PS1 transgenic mouse model of Alzheimer's disease.Validation of the multimodal assessment of capacities in severe dementia: a novel cognitive and functional scale for use in severe dementia.Rapidly Versus Slowly Progressing Patients With Alzheimer's Disease: Differences in Baseline Cognition.Can 8 months of daily tDCS application slow the cognitive decline in Alzheimer's disease? A case study.Usefulness of peripapillary nerve fiber layer thickness assessed by optical coherence tomography as a biomarker for Alzheimer's disease
P2860
Q30380874-0F1B1651-57CA-4C0F-8510-F72EBE5B2AA5Q31147579-14D6CE44-CB58-4A19-ABFE-25405882241CQ34372593-22888266-54F6-4C3E-89CD-1EF3F215FA6AQ34418781-7D7606D3-ACB6-417B-BC40-B46C5F4A00A3Q34762064-1A060023-A154-4AAA-93F6-8C2BF82FEA6CQ35154263-38D19D59-B931-4B89-9C95-0A3BD7247D21Q35675943-7BE9D535-FA1C-449C-BCCC-DB3EAA5DB662Q35811161-D49B5F7F-6C6E-493E-A893-450BE6AB10BDQ36576472-D181842E-20FA-4A6D-93B9-E3FADF560AFEQ36659366-A68EB8F7-3447-4770-B4A8-59CB9A8563AAQ36818762-8DE13DCE-8D0B-4B62-BC09-2CF5DCFC2C5EQ37487612-0E820397-33BB-49D8-A87F-EA4F189CCF40Q38150708-33211EC6-D251-4ECB-9BFA-AED5276E5E75Q38693438-3AEC39D2-0ADE-4AAD-9F4B-7F19D3A9AC03Q41444056-945397D9-D59A-4922-AAA4-F72D1C48650BQ47958145-4A194011-F27A-41A5-9C15-8A5852A8ADB0Q48248276-AAF614ED-7283-4AD9-8E60-083E1EDF9771Q50595097-FE7DDFE4-1472-4D30-BC12-7B8D6EBB7D45Q50689821-B5D721DA-02B8-473D-A2F2-69BFEF51151AQ53304765-11D97AF8-42EF-41DE-B5DF-02DCDCFC675CQ58612352-385DF747-38DE-463C-A06F-F6A54387B483
P2860
Age and rate of cognitive decline in Alzheimer disease: implications for clinical trials.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Age and rate of cognitive decline in Alzheimer disease: implications for clinical trials.
@en
Age and rate of cognitive decline in Alzheimer disease: implications for clinical trials.
@nl
type
label
Age and rate of cognitive decline in Alzheimer disease: implications for clinical trials.
@en
Age and rate of cognitive decline in Alzheimer disease: implications for clinical trials.
@nl
prefLabel
Age and rate of cognitive decline in Alzheimer disease: implications for clinical trials.
@en
Age and rate of cognitive decline in Alzheimer disease: implications for clinical trials.
@nl
P2093
P1433
P1476
Age and rate of cognitive decline in Alzheimer disease: implications for clinical trials.
@en
P2093
Charles Bernick
Rema Raman
Xiaoying Sun
P304
P356
10.1001/ARCHNEUROL.2011.3758
P577
2012-07-01T00:00:00Z